Preparation & Measurement Guide

CJC-1295 + Ipamorelin 5mg+5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a CJC-1295 + Ipamorelin 5mg+5mg vial.

Research use only Educational summary of a commonly documented convention. Not approved for human use.
Vial Size 5mg CJC-1295 + 5mg Ipamorelin
Preparation 2mL bacteriostatic water
Concentration 5mg/mL after preparation
Documented Convention 100-200mcg of each once daily

1. Preparation and Measurement

CJC-1295 + Ipamorelin 5mg+5mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 100mcg CJC-1295 + 100mcg Ipamorelin once daily 0.04mL / 4 units
Weeks 3-4 150mcg CJC-1295 + 150mcg Ipamorelin once daily 0.06mL / 6 units
Weeks 5-8 200mcg CJC-1295 + 200mcg Ipamorelin once daily 0.08mL / 8 units

Vial estimate: One 10mg vial contains approximately 50 administrations at the first listed amount or 25 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Some entries are very small measurements; account for the accuracy of the measuring device.
  • The vial contains 5mg CJC-1295 + 5mg Ipamorelin; all measurements preserve that fixed component ratio.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • CJC-1295 + Ipamorelin 5mg+5mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

CJC-1295 and ipamorelin have each been studied for effects on growth-hormone signalling, but published studies do not validate this exact combined vial or the staged schedule shown here.

The blend is not an approved therapeutic drug. Component evidence cannot establish the safety or efficacy of the combined research material.

Primary Research and Regulatory References

  1. CJC-1295 growth-hormone and IGF-1 study
  2. CJC-1295 pharmacokinetic study
  3. Ipamorelin growth-hormone secretagogue study

Research Materials

Review CJC-1295 + Ipamorelin 5mg+5mg Product Information

View CJC-1295 + Ipamorelin 5mg+5mg Browse Growth Hormone Research

← Back to Dosage Protocols

Research-use disclaimer: CJC-1295 + Ipamorelin 5mg+5mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.